Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
arcticnovartis
Thu, 06/12/2025 – 08:04
Read more about Novartis Fabhalta® shows statistically significan…
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
arcticnovartis
Mon, 06/02/2025 – 07:19
Read more about Novartis Pluvicto™ …
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
arcticnovartis
Sun, 06/01/2025 – 15:04
Read more about Novartis Kisqali® reduces risk of recurrence in younger patients with ear…
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
arcticnovartis
Tue, 05/27/2025 – 14:04
Read more about Novartis announces commencement of tender offer to acquire Regulus Therapeutics
Basel, May 27, 2…
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
arcticnovartis
Thu, 05/15/2025 – 15:04
Read more about New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising …
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis erzielt im zweiten Quarta…
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis Scembl…
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Latest analysis of No…
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis atrasentan Phase III data show clinica…
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis Phase III data confirm sustained efficacy and long-term s…